iconiifl-logo-icon 1
IIFL

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

  • Open Demat with exclusive Advice & Services
  • Get a dedicated Relationship Manager to help you grow your wealth
  • Exclusive advisory on 20+ trading & wealth-based investment options
  • One tap Investments, Automated trading & much more
  • Minimum 1 lakh margin required
sidebar image

Supriya Lifescience appoints Rajeev Kumar Jain as Chief Executive Officer -; KMP

3 Oct 2022 , 03:26 PM

He has over 35+ years of rich functional experience in the manufacturing domain of Bulk Drugs, Intermediate and API with a "Safety First, Quality Must and EBIDTA Growth" mindset.
Supriya Lifescience Ltd has announced appointment of Rajeev Kumar Jain as Chief Executive Officer (CEO) & Key Managerial Personnel (KMP) w.e.f. October 3, 2022.

Rajeev Jain is a Master of Business Administration (Marketing) from Jivaji University, Gwalior and B Sc (PCB) with distinction. Additionally, he has taken part in business seminars and workshops on corporate transformation in China, Germany, and the Netherlands.

He has over 35+ years of rich functional experience in the manufacturing domain of Bulk Drugs, Intermediate and API with a "Safety First, Quality Must and EBIDTA Growth" mindset.

He is very skilled and experienced in managing regulations and guidelines, such as those from the USFDA, KFDA, EMA, ANVISA, CDSCO, ISO, PMDA, and IDL CHINA.

Throughout his career, he has maintained an impeccable record with reputable companies like Morepen Labs Ltd., Ind Swift Labs, Arch Pharma, Trident Group, Max India (DSM), etc.

He has strategic leadership attributes with a global mindset and has demonstrated lead for cross functional teams with end-to-end solutions & managing optimal utilization of Men, Machine & Material.

Rajiv is the right leader for Supriya Lifescience limited," said Dr. Satish Wagh, Chairman & Managing Director. Rajiv's extensive pharma background and shopfloor skills should help Supriya strengthen manufacturing excellence, develop strategic alliances and expand our international sales presence. We believe his strong leadership experience will help take Supriya to the next level of growth."

"I am very excited to be joining the Supriya team," said Rajiv Kumar Jain. "I believe Supriya has a great business model and talented management team that uniquely positions it to capitalize on the changing Pharmaceutical environment. As the industry evolves, I believe Supriya is in a position to reach newer heights with backward integration, focus on R&D, increasing capacity, and capitalizing on CMO/CDMO potential. Our endeavor would be to achieve healthy revenue growth with healthy margins and upgrade to the evolving GMP and EHS standards."

At around 3:11 PM, Supriya Lifescience Ltd is currently trading at Rs301 per share up by Rs1.05 or 0.35% from its previous closing of Rs299.95 per share on the BSE.

For feedback and suggestions, write to us at editorial@iifl.com

Related Tags

  • appointment
  • CEO
  • Chief Executive Officer
  • news
  • Supriya Lifescience
  • Supriya Lifescience shares
  • Supriya Lifescience stocks
sidebar mobile

BLOGS AND PERSONAL FINANCE

Images
4 Mar 2024   |   06:49 AM
Images
19 Feb 2024   |   09:29 AM
Read More

Most Read News

4 Mar 2024   |   09:10 AM
4 Mar 2024   |   08:43 AM
4 Mar 2024   |   08:40 AM
3 Mar 2024   |   12:26 PM
Read More
Knowledge Centerplus
Logo

Logo IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000

Logo IIFL Securities Support WhatsApp Number
+91 9892691696

Download The App Now

appapp
Knowledge Centerplus

Follow us on

facebooktwitterrssyoutubeinstagramlinkedin

2024, IIFL Securities Ltd. All Rights Reserved

ATTENTION INVESTORS
  • Prevent Unauthorized Transactions in your demat / trading account Update your Mobile Number/ email Id with your stock broker / Depository Participant. Receive information of your transactions directly from Exchanges on your mobile / email at the end of day and alerts on your registered mobile for all debits and other important transactions in your demat account directly from NSDL/ CDSL on the same day." - Issued in the interest of investors.
  • KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary.
  • No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account."

www.indiainfoline.com is part of the IIFL Group, a leading financial services player and a diversified NBFC. The site provides comprehensive and real time information on Indian corporates, sectors, financial markets and economy. On the site we feature industry and political leaders, entrepreneurs, and trend setters. The research, personal finance and market tutorial sections are widely followed by students, academia, corporates and investors among others.

RISK DISCLOSURE ON DERIVATIVES
  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to Rs. 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.
Copyright © IIFL Securities Ltd. All rights Reserved.

Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248

plus
We are ISO 27001:2013 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.